Sana Biotechnology (NASDAQ:SANA) reported quarterly losses of $(0.48) per share. This is a 29.73 percent decrease over losses of $(0.37) per share from the same period last year.
Pfizer Embraces Direct-To-Consumer Model For Covid Antiviral, Says Comirnaty Revenues Continue To Perform Consistently With Expectations
Pfizer reports Q1 results: adjusted EPS beats estimates, driven by revenue growth. Significant declines in Comirnaty and Paxlovid revenues countered by operational gains. Company announces plans for direct-to-consumer online platform.
